The study detailed the results of a trial involving 2,246 unvaccinated, nonhospitalized patients at high risk of their case progressing to severe COVID-19. The researchers gave 1,120 participants Paxlovid and the other 1,126 participants received a placebo.
Participants in the Paxlovid group were 88.9 percent less likely to die or be hospitalized compared with those in the placebo group. The pill presented no evident safety concerns, according to the study.
Read the full study here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
